Rosiglitazone attenuates endothelin-1-induced vasoconstriction by upregulating endothelial expression of endothelin b receptor

Hypertension

Volumn 56, Issue 1, 2010, Pages 129-135

  Tian, Jianwei ^a,b   Wong, Wing Tak ^c   Tian, Xiao Yu ^c   Zhang, Peng ^a   Huang, Yu ^c   Wang, Nanping ^a  

^a PEKING UNIVERSITY   (China)

^b AIR FORCE GENERAL HOSPITAL   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

ETBR; PPAR ; Thiazolidinediones; Vasoconstriction

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; NITRIC OXIDE SYNTHASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SARAFOTOXIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MESENTERIC ARTERY; MOUSE; MYOGRAPHY; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASOCONSTRICTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; RECEPTOR, ENDOTHELIN B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; THIAZOLIDINEDIONES; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 77953810565     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.150375     Document Type: Article

References (33)

1. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-y-mediated effects in the vasculature. Circ Res. 2008;102: 283-294.
2. Lehrke M, Lazar MA. The many faces of PPARy. Cell. 2005;123: 993-999.
3. Chetty VT, Sharma AM. Can PPARy agonists have a role in the management of obesity-related hypertension? Vascul Pharmacol. 2006;45: 46-53.
4. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf). 2009;196:193-222.
5. Wang N, Verna L, Chen NG, Chen J, Li H, Forman BM, Stemerman MB. Constitutive activation of peroxisome proliferator-activated receptor-y suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem. 2002;277:34176-34181.
6. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999;85:394-402.
7. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. PPAR(y) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension. 2004;43: 661-666.
8. Iglarz M, Touyz RM, Viel EC, Paradis P, Amiri F, Diep QN, Schiffrin EL. Peroxisome proliferator-activated receptor-a and receptor-y activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension. 2003;42:737-743.
9. Martin-Nizard F, Furman C, Delerive P, Kandoussi A, Fruchart JC, Staels B, Duriez P. Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J Cardiovasc Pharmacol. 2002;40:822-831.
10. Matsumoto T, Noguchi E, Kobayashi T, Kamata K. Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats. Free Radic Biol Med. 2007;42:993-1007.
11. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
12. Huang Y, Chan FL, Lau CW, Tsang SY, Chen ZY, He GW, Yao X. Roles of cyclic AMP and Ca2 +-activated K+ channels in endothelium-independent relaxation by urocortin in the rat coronary artery. Cardiovasc Res. 2003;57:824-833.
13. Wong SL, Leung FP, Lau CW, Au CL, Yung LM, Yao X, Chen ZY, Vanhoutte PM, Gollasch M, Huang Y. Cyclooxygenase-2-derived prostaglandin F2a mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ Res. 2009;104: 228-235.
14. Munter K, Kirchengast M. The role of endothelin receptor antagonists in cardiovascular pharmacotherapy. Expert Opin Emerg Drugs. 2001; 6:3-11. (Pubitemid 32381374)
15. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004;61:227-237. (Pubitemid 38091763)
16. Sanchez R, MacKenzie A, Farhat N, Nguyen TD, Stewart DJ, Mercier I, Calderone A, Thorin E. Endothelin B receptor-mediated regulation of endothelin-1 content and release in cultured porcine aorta endothelial cell. J Cardiovasc Pharmacol. 2002;39:652-659.
17. Orleans-Juste P, Labonte J, Bkaily G, Choufani S, Plante M, Honore JC. Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther. 2002;95:221-238.
18. Bohm F, Pernow J, Lindstrom J, Ahlborg G. ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Lond). 2003; 104:143-151.
19. Schiffrin EL, Lariviere R, Touyz RM. ETA and ETB receptors on vascular smooth muscle cells from mesenteric vessels of spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1995;22(suppl): S193-S194. (Pubitemid 26062077)
20. Bao Y, Li R, Jiang J, Cai B, Gao J, Le K, Zhang F, Chen S, Liu P. Activation of peroxisome proliferator-activated receptor yinhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway. Mol Cell Biochem. 2008;317:189-196.
21. Bae EH, Kim IJ, Ma SK, Kim SW. Rosiglitazone prevents the progression of renal injury in DOCA-salt hypertensive rats. Hypertens Res. 2010;33:255-262.
22. Venegas-Pont M, Sartori-Valinotti JC, Maric C, Racusen LC, Glover PH, McLemore GR Jr, Jones AV, Reckelhoff JF, Ryan MJ. Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol. 2009;296:R1282-R1289.
23. Ledingham JM, Laverty R. Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats. Clin Exp Pharmacol Physiol. 2005;32: 919-925.
24. Potenza MA, Gagliardi S, De BL, Zigrino A, Tiravanti E, Colantuono G, Federici A, Lorusso L, Benagiano V, Quon MJ, Montagnani M. Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature. Am J Physiol Endocrinol Metab. 2009;297:E685-E694
25. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053-1059.
26. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342: 905-912.
27. Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM, Bank AJ. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc Med. 2007;12:311-318.
28. Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazo-lidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes. 1999;48:1448-1453.
29. Min KM, Park SW, Cho KY, Song MS, Kim DK, Park GS, Lee MK. Troglitazone improves blood flow by inhibiting neointimal formation after balloon injury in Otsuka Long-Evans Tokushima fatty rats. Metabolism. 2002;51:998-1002.
30. Halabi CM, Beyer AM, de Lange WJ, Keen HL, Baumbach GL, Faraci FM, Sigmund CD. Interference with PPARy function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab. 2008;7: 215-226.
31. Ketsawatsomkron P, Pelham CJ, Groh S, Keen HL, Faraci FM, Sigmund CD. Does peroxisome proliferator-activated receptor-y (PPARy) protect from hypertension directly through effects in the vasculature? J Biol Chem. 2010;285:9311-9316.
32. Wang N, Yang G, Jia Z, Zhang H, Aoyagi T, Soodvilai S, Symons JD, Schnermann JB, Gonzalez FJ, Litwin SE, Yang T. Vascular PPARy controls circadian variation in blood pressure and heart rate through Bmal1. Cell Metab. 2008;8:482-491.
33. Wang N, Symons JD, Zhang H, Jia Z, Gonzalez FJ, Yang T. Distinct functions of vascular endothelial and smooth muscle PPARy in regulation of blood pressure and vascular tone. Toxicol Pathol. 2009;37:21-27.